Skip to content

Intervention For Adolescents and Young Adults (AYAs) With Cancer Risk Syndromes

AYA-RISE: Refining a Scalable, Patient- and Family-centered Intervention to Improve Cancer Risk Communication and Decision-making Among Adolescents and Young Adults With Cancer Risk Syndromes

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04323774
Acronym
AYA-RISE
Enrollment
115
Registered
2020-03-27
Start date
2021-03-01
Completion date
2027-06-30
Last updated
2026-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer Risk Syndrome

Keywords

Cancer Risk Syndrome, LiFraumeni Syndrome Association (LFSA) Youth Conference

Brief summary

This research is being done because there is a need to improve cancer risk communication and decision-making among adolescents and young adults. In this study, the investigators are looking at whether using a chatbot and online portal for cancer risk information helps improve communication and decision-making. * Over 70,000 adolescents and young adults (AYAs) are diagnosed with cancer in the U.S. every year and up to 10% have genetic changes (or, mutations) that put them at a higher risk of developing new cancers during their lifetimes. These genetic mutations can result in cancer risk syndromes (such as, Lynch Syndrome or Li-Fraumeni Syndrome). Identifying cancer risk syndromes can allow for screening and early diagnosis of future cancers, which could ultimately save lives and offer more care choices for patients. As a result, genetic counseling and testing for cancer risk syndromes is being recommended more for Adolescents and Young Adults with new cancer diagnoses, regardless of family history. * This research study to develop an intervention called AYA-RISE that aims to assist AYAs with cancer risk communication and decision-making around their caregivers.

Detailed description

This research study involves three aims (Aims 1, 2, and 3). * Aim 1, Part 1, which focuses on finding the best format for the study intervention (called AYA-RISE); whether AYA-RISE is easy to use; and whether patients, family caregivers, and providers find AYA-RISE acceptable.The research study procedures include: * Using and reviewing AYA-RISE, * Participating in audio-recorded, 30-minute interviews * Aim 1, Part 2, which is a pilot study of the study intervention (called AYA-RISE). In this pilot study, the investigators are looking at whether AYA-RISE is easy to use and what participants think of it. \-- The activities involved in this part of the study are: * Baseline Questionnaire * Using and reviewing AYA-RISE * Follow-up Questionnaire * Brief feedback interviews on AYA-RISE * In Aim 2, participants will be randomized trial into one of two groups; * Group 1: Standard Genetic Counseling/follow-up visit or * Group 2 : Standard Genetic Counseling/follow-up visit and Access to AYA-Rise * Aim 3: Semi-Structured Interviews: * Evaluate implementation outcomes using 28 semi-structured interviews with patients, family members, providers, and site principal investigators

Interventions

BEHAVIORALAYA-RISE Adolescents and Young Adults Risk Information and Screening Education

A chatbot is a computer program that can chat with humans. The text the chatbot uses to talk with humans was created by real people, but the chatbot itself is not a real person. A company called Clear Genetics developed the original chatbot and patient portal, and this study team customized it for this research study.

BEHAVIORALStandard clinical visit for genetic counseling

Standard clinical visit for genetic counseling and follow up

Sponsors

Dana-Farber Cancer Institute
Lead SponsorOTHER
National Cancer Institute (NCI)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
12 Years to 24 Years
Healthy volunteers
Yes

Inclusion criteria

* Across all study aims, we will enroll AYA patients, family members/caregivers, and providers. AIM 1, PART 1 - STAKEHOLDER INTERVIEWS AYA Patients 1. Ages 12-24 years, inclusive 2. Diagnosed with a cancer risk syndrome 3. English-speaking and -reading 4. Receiving care at any of the study sites OR participating in the LiFraumeni Syndrome Association (LFSA) Youth Conference 5. Adequate cognitive function per NeuroQOL indicated by a score of 30 or greater 6. Not receiving active cancer therapy Family caregivers-Inclusion Criteria 1. Parent/guardian, spouse/partner, or other family member who participates in the care of AYAs aged 12-24 with cancer risk syndromes 2. English-speaking and -reading 3. At any of the study sites Providers Inclusion Criteria (Oncologists, nurses, genetic counselors, social workers, or psychologists) 1. English-speaking and reading 2. Caring for AYAs aged 12-24 with cancer risk syndromes at any of the study sites AIM 1, PART 2 - INTERVENTION PILOT AYA Patients 1. Ages 12-24 years, inclusive 2. Diagnosed with a cancer risk syndrome 3. English-speaking and -reading 4. Receiving care at Dana-Farber Cancer Institute 5. Adequate cognitive function per NeuroQOL, indicated by a score of 30 or greater 6. Not receiving active cancer therapy 7. Did not participate in a stakeholder interview Eligibility notes: * Family caregivers of participating 12-17y patients will be eligible to participate in the pilot * 12-17y patients can participate without a family member if both the patient and family member agree. * Patients 18-24y will have the option to participate with or without a family member. AIM 2 - RANDOMIZED TRIAL AYA Patients 1. Ages 12-24 years, inclusive 2. Diagnosed with a cancer risk syndrome 3. English-speaking and reading 4. Has a planned post-disclosure genetic counseling or follow-up visit at any of the study sites 5. Adequate cognitive function per NeuroQOL, indicated by a score of 30 or greater 6. Not receiving active cancer therapy 7. Did not participate in either part of Aim 1 (interview or pilot) Family caregivers 1. Parent/guardian, spouse/partner, or other family member who participates in the care of AYAs aged 12-24 with cancer risk syndromes 2. English-speaking and -reading 3. At any of the study sites 4. Did not participate in either part of Aim 1 (interview or pilot) AIM 3 - SEMI-STRUCTURED INTERVIEWS AYA Patients, Family Caregivers, Providers, and Site PIs 1. Participated in the intervention arm of Aim 2, or 2. Is a site principal investigator at one of the 4 participating study sites

Design outcomes

Primary

MeasureTime frameDescription
Percentage of Consenting AYA use AYA-RISE2 yearsThe feasibility (\>70% consenting AYAs use AYA-RISE through the risk communication step of the chat and patient portal, based on use data from Clear Genetics)
Percentage of Acceptability2 yearsAcceptability (\>70% AYAs consider the intervention acceptable, measured as a post-test AIM score \>4.)
Change in patient knowledge of cancer risk and screeningbaseline to post-visit surveys up to 24 monthsThis change will be measured by baseline and post-visit survey responses on the Knowledge of Cancer Screening and Gist Comprehension of Genetic Cancer Risk measures.
Change in psychological distressbaseline to post-visit surveys up to 24 monthsThis change will be measured by baseline and post-visit survey responses using the psychosocial aspects of hereditary cancer (PAHC) measure.
Patient ownership of information in the intervention arm24 Monthsdetermined as % AYAs able to store and access portal information
Participants who followed up for recommended carescreening and follow-up over the next year up to 24 MonthsWe will identify recommended care and screening via medical record review, and whether care was received, post-visit.
Utilization of AYA-RISE2 YearsChat transcripts and patient portal access
Acceptability of AYA-RISE2 YearsSemi-structured interview: How did patients, providers, family members feel about the intervention? Was the experience positive, negative, or neutral? An analytic matrix on intervention design will be used to code of semi-structured interviews
Adoption of AYA-RISE2 YearsAn analytic matrix on intervention design will be used to code of semi-structured interviews \- Semi-structured interview of Providers and Clinic Leaders * Were patients and providers willing to try the intervention? * Would they want to continue to use the intervention?
Practicality of Using AYA-RISE2 YearsAn analytic matrix on intervention design will be used to code of semi-structured interviews: Site PI Semi-structured interview * Is it practical to continue to use AYA-RISE within constraints of * clinic, provider, and patient/family needs?
Fidelity of AYA-RISE2 Years* Site RA: Observation and Checklist * Does actual implementation match the planned process?
Sustainability of AYA-Rise2 YearsAn analytic matrix on intervention design will be used to code of semi-structured interviews Can the processes required for AYA-RISE be maintained beyond the research setting?

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORJennifer Mack, MD

Dana-Farber Cancer Institute

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 30, 2026